- Home
- GLMD vs CERO Comparison
GLMD vs CERO Comparison
Compare GLMD & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- CERO
- Stock Information
- Founded
- GLMD 2000
- CERO 2017
- Country
- GLMD Israel
- CERO United States
- Employees
- GLMD N/A
- CERO N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- CERO
- Sector
- GLMD Health Care
- CERO
- Exchange
- GLMD Nasdaq
- CERO Nasdaq
- Market Cap
- GLMD 3.0M
- CERO 3.5M
- IPO Year
- GLMD 2014
- CERO N/A
- Fundamental
- Price
- GLMD $1.83
- CERO $9.41
- Analyst Decision
- GLMD Hold
- CERO Strong Buy
- Analyst Count
- GLMD 1
- CERO 2
- Target Price
- GLMD N/A
- CERO $45.00
- AVG Volume (30 Days)
- GLMD 353.4K
- CERO 3.3M
- Earning Date
- GLMD 05-22-2025
- CERO 08-13-2025
- Dividend Yield
- GLMD N/A
- CERO N/A
- EPS Growth
- GLMD N/A
- CERO N/A
- EPS
- GLMD N/A
- CERO N/A
- Revenue
- GLMD N/A
- CERO N/A
- Revenue This Year
- GLMD N/A
- CERO N/A
- Revenue Next Year
- GLMD N/A
- CERO N/A
- P/E Ratio
- GLMD N/A
- CERO N/A
- Revenue Growth
- GLMD N/A
- CERO N/A
- 52 Week Low
- GLMD $1.15
- CERO $6.71
- 52 Week High
- GLMD $23.80
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- GLMD 60.37
- CERO 47.59
- Support Level
- GLMD $1.74
- CERO $9.10
- Resistance Level
- GLMD $1.91
- CERO $9.73
- Average True Range (ATR)
- GLMD 0.12
- CERO 2.72
- MACD
- GLMD -0.00
- CERO 0.09
- Stochastic Oscillator
- GLMD 71.95
- CERO 13.44
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.